guanfacine has been researched along with Child Development Disorders, Pervasive in 9 studies
Guanfacine: A centrally acting antihypertensive agent with specificity towards ADRENERGIC ALPHA-2 RECEPTORS.
Child Development Disorders, Pervasive: Severe distortions in the development of many basic psychological functions that are not normal for any stage in development. These distortions are manifested in sustained social impairment, speech abnormalities, and peculiar motor movements.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Guanfacine has been shown to reduce hyperactive behaviors in children with attention-deficit/hyperactivity disorder (ADHD) and possibly in children with pervasive developmental disorder (PDD) and hyperactivity." | 2.75 | Possible influence of variant of the P-glycoprotein gene (MDR1/ABCB1) on clinical response to guanfacine in children with pervasive developmental disorders and hyperactivity. ( Aman, MG; Arnold, LE; McCracken, JT; McDougle, CJ; Posey, D; Ritz, L; Scahill, L; Shiraga, S; Tierney, E; Vitiello, B; Whelan, F, 2010) |
| "Guanfacine was well tolerated, and did not lead to significant changes in blood pressure or heart rate." | 1.32 | Guanfacine treatment of hyperactivity and inattention in pervasive developmental disorders: a retrospective analysis of 80 cases. ( Kem, DL; McDougle, CJ; Posey, DJ; Puntney, JI; Sasher, TM, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (66.67) | 29.6817 |
| 2010's | 3 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fernández-Jaén, A | 1 |
| Martín Fernández-Mayoralas, D | 1 |
| Fernández-Perrone, AL | 1 |
| Calleja-Pérez, B | 1 |
| Muñoz-Jareño, N | 1 |
| López-Arribas, S | 1 |
| Scahill, L | 4 |
| McCracken, JT | 2 |
| Aman, MG | 2 |
| McDougle, CJ | 6 |
| Tierney, E | 2 |
| Shiraga, S | 1 |
| Whelan, F | 1 |
| Arnold, LE | 2 |
| Posey, D | 2 |
| Ritz, L | 2 |
| Vitiello, B | 2 |
| Blankenship, K | 1 |
| Erickson, CA | 1 |
| Stigler, KA | 1 |
| Posey, DJ | 3 |
| Puntney, JI | 1 |
| Sasher, TM | 1 |
| Kem, DL | 1 |
| Dziura, J | 1 |
| Young, C | 1 |
| Shah, B | 1 |
| Ghuman, J | 1 |
| Pachler, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Multi-Center, Open Label, Evaluation of the Effect and Safety of Lisdexamfetamine in Children Aged 6-12 With Attention Deficit Hyperactivity Disorder and Autism Spectrum Disorder[NCT03337646] | Phase 4 | 48 participants (Actual) | Interventional | 2018-09-26 | Active, not recruiting | ||
| Methylphenidate for Hyperactivity and Impulsiveness in Children and Adolescents With Pervasive Developmental Disorders[NCT00025779] | 60 participants | Interventional | 2001-10-31 | Completed | |||
| Characterization of Endogenous Melatonin Profiles in Children With Autism Spectrum Disorder.[NCT00691080] | 58 participants (Actual) | Observational | 2007-09-30 | Completed | |||
| Guanfacine for the Treatment of Hyperactivity in Pervasive Developmental Disorder[NCT01238575] | Phase 4 | 62 participants (Actual) | Interventional | 2011-12-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"The Aberrant Behavior Checklist (ABC) is a symptom checklist for assessing problem behaviors in individuals ages 6 to 54 with mental retardation. The full ABC is a 58-item parent-rating with five factors: Irritability, Social Withdrawal, Stereotypy, Hyperactivity and Inappropriate Speech.~The 16-item Hyperactivity subscale covers over-activity (7 items), impulsiveness (2 items), inattention (3 items) and noncompliance (4 items). It has been used as a primary outcome measure in several trials of children with developmental disabilities. The interpretation of the tool and its sub-scales is that a greater number of items, indicates greater severity. The range of scores is 0 to 48." (NCT01238575)
Timeframe: Baseline
| Intervention | units on a scale (Mean) |
|---|---|
| Extended-release Guanfacine | 34.4 |
| Inactive Placebo | 34.25 |
The Aberrant Behavior Checklist (ABC) is a symptom checklist for assessing problem behaviors in individuals ages 6 to 54 with mental retardation. The full ABC is a 58-item parent-rating with five factors: Irritability, Social Withdrawal, Stereotypy, Hyperactivity and Inappropriate Speech. The 16-item Hyperactivity subscale covers over-activity (7 items), impulsiveness (2 items), inattention (3 items) and noncompliance (4 items). It has been used as a primary outcome measure in several trials of children with developmental disabilities. The interpretation of the tool and its sub-scales is that a greater number of items, indicates greater severity. The range of scores is 0 to 48. (NCT01238575)
Timeframe: Week 8
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Extended-release Guanfacine | 19.3 |
| Inactive Placebo | 29.7 |
The Aberrant Behavior Checklist (ABC) is a symptom checklist for assessing problem behaviors in individuals ages 6 to 54 with mental retardation. The full ABC is a 58-item parent-rating with five factors: Irritability, Social Withdrawal, Stereotypy, Hyperactivity and Inappropriate Speech. It has been used as a primary outcome measure in several trials of children with developmental disabilities. The interpretation of the tool and its sub-scales is that a greater number of items, indicates greater severity. This subscale's scores can range from 0 to 12. (NCT01238575)
Timeframe: 8 weeks
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Extended-release Guanfacine | 4.2 |
| Inactive Placebo | 5.99 |
The Aberrant Behavior Checklist (ABC) is a symptom checklist for assessing problem behaviors in individuals ages 6 to 54 with mental retardation. The full ABC is a 58-item parent-rating with five factors: Irritability, Social Withdrawal, Stereotypy, Hyperactivity and Inappropriate Speech. It has been used as a primary outcome measure in several trials of children with developmental disabilities. The interpretation of the tool and its sub-scales is that a greater number of items, indicates greater severity. This subscale's scores can range from 0 to 12. (NCT01238575)
Timeframe: Baseline
| Intervention | units on a scale (Mean) |
|---|---|
| Extended-release Guanfacine | 6.33 |
| Inactive Placebo | 6.84 |
The Aberrant Behavior Checklist (ABC) is a symptom checklist for assessing problem behaviors in individuals ages 6 to 54 with mental retardation. It is a 58 item checklist which takes about 10 - 15 minutes to complete. There are five subscales: a) Irritability and Agitation b) Lethargy and Social Withdrawal c) Stereotypic Behavior d) Hyperactivity and Noncompliance and e) Inappropriate Speech. The higher the number of items (score), the greater the amount of symptoms. Scores can range from 0 to 45. (NCT01238575)
Timeframe: 8 weeks
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Extended-release Guanfacine | 13.5 |
| Inactive Placebo | 16.1 |
The Aberrant Behavior Checklist (ABC) is a symptom checklist for assessing problem behaviors in individuals ages 6 to 54 with mental retardation. The full ABC is a 58-item parent-rating with five factors: Irritability, Social Withdrawal, Stereotypy, Hyperactivity and Inappropriate Speech. It has been used as a primary outcome measure in several trials of children with developmental disabilities. The interpretation of the tool and its sub-scales is that a greater number of items, indicates greater severity. Scores for this subscale can range from 0 to 45. (NCT01238575)
Timeframe: Baseline
| Intervention | units on a scale (Mean) |
|---|---|
| Extended-release Guanfacine | 20.3 |
| Inactive Placebo | 18.06 |
The Aberrant Behavior Checklist (ABC) is a symptom checklist for assessing problem behaviors in individuals ages 6 to 54 with mental retardation. The full ABC is a 58-item parent-rating with five factors: Irritability, Social Withdrawal, Stereotypy, Hyperactivity and Inappropriate Speech. It has been used as a primary outcome measure in several trials of children with developmental disabilities. The interpretation of the tool and its sub-scales is that a greater number of items, indicates greater severity. This subscale's scores can range from 0 to 48. (NCT01238575)
Timeframe: 8 weeks
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Extended-release Guanfacine | 9.8 |
| Inactive Placebo | 8.6 |
The Aberrant Behavior Checklist (ABC) is a symptom checklist for assessing problem behaviors in individuals ages 6 to 54 with mental retardation. The full ABC is a 58-item parent-rating with five factors: Irritability, Social Withdrawal, Stereotypy, Hyperactivity and Inappropriate Speech. It has been used as a primary outcome measure in several trials of children with developmental disabilities. The interpretation of the tool and its sub-scales is that a greater number of items, indicates greater severity. This subscale's scores can range from 0 to 48. (NCT01238575)
Timeframe: Baseline
| Intervention | units on a scale (Mean) |
|---|---|
| Extended-release Guanfacine | 13.6 |
| Inactive Placebo | 12.06 |
The Aberrant Behavior Checklist (ABC) is a symptom checklist for assessing problem behaviors in individuals ages 6 to 54 with mental retardation. The full ABC is a 58-item parent-rating with five factors: Irritability, Social Withdrawal, Stereotypy, Hyperactivity and Inappropriate Speech. It has been used as a primary outcome measure in several trials of children with developmental disabilities. The interpretation of the tool and its sub-scales is that a greater number of items, indicates greater severity. This subscale's scores can range from 0 to 21. (NCT01238575)
Timeframe: 8 weeks
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Extended-release Guanfacine | 3.6 |
| Inactive Placebo | 5.9 |
The Aberrant Behavior Checklist (ABC) is a symptom checklist for assessing problem behaviors in individuals ages 6 to 54 with mental retardation. The full ABC is a 58-item parent-rating with five factors: Irritability, Social Withdrawal, Stereotypy, Hyperactivity and Inappropriate Speech. It has been used as a primary outcome measure in several trials of children with developmental disabilities. The interpretation of the tool and its sub-scales is that a greater number of items, indicates greater severity. This subscale's scores can range from 0 to 21. (NCT01238575)
Timeframe: Baseline
| Intervention | units on a scale (Mean) |
|---|---|
| Extended-release Guanfacine | 8.53 |
| Inactive Placebo | 9.31 |
The ADHD Rating Scale (ADHD-RS) is an 18-item scale directly derived from DSM-IV criteria for Attention Deficit Hyperactivity Disorder with established reliability, validity and sensitivity to change. The ADHD Rating Scale-IV is completed independently by the parent and scored by a clinician. The scale consists of 2 subscales: inattention (9 items) and hyperactivity-impulsivity (9 items). If 3 or more items are skipped, the clinician should use extreme caution in interpreting the scale. Results from this rating scale alone should not be used to make a diagnosis. This subscale can range from 0 to 27 for scoring, with a higher score indicating greater severity. (NCT01238575)
Timeframe: Baseline
| Intervention | units on a scale (Mean) |
|---|---|
| Extended-release Guanfacine | 19.00 |
| Inactive Placebo | 19.5 |
The ADHD Rating Scale (ADHD-RS) is an 18-item scale directly derived from DSM-IV criteria for Attention Deficit Hyperactivity Disorder with established reliability, validity and sensitivity to change. The ADHD Rating Scale-IV is completed independently by the parent and scored by a clinician. The scale consists of 2 subscales: inattention (9 items) and hyperactivity-impulsivity (9 items). If 3 or more items are skipped, the clinician should use extreme caution in interpreting the scale. Results from this rating scale alone should not be used to make a diagnosis. This subscale can range from 0 to 27 for scoring,with a higher score indicating greater severity. (NCT01238575)
Timeframe: 8 weeks
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Extended-release Guanfacine | 10.6 |
| Inactive Placebo | 18.7 |
The ADHD Rating Scale (ADHD-RS) is an 18-item scale directly derived from DSM-IV criteria for Attention Deficit Hyperactivity Disorder with established reliability, validity and sensitivity to change. The ADHD Rating Scale-IV is completed independently by the parent and scored by a clinician. The scale consists of 2 subscales: inattention (9 items) and hyperactivity-impulsivity (9 items). If 3 or more items are skipped, the clinician should use extreme caution in interpreting the scale. Results from this rating scale alone should not be used to make a diagnosis. This subscale can range from 0 to 27 for scoring, with a higher score indicating greater severity. (NCT01238575)
Timeframe: 8 weeks
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Extended-release Guanfacine | 14.7 |
| Inactive Placebo | 19.5 |
The ADHD Rating Scale (ADHD-RS) is an 18-item scale directly derived from DSM-IV criteria for Attention Deficit Hyperactivity Disorder with established reliability, validity and sensitivity to change. The ADHD Rating Scale-IV is completed independently by the parent and scored by a clinician. The scale consists of 2 subscales: inattention (9 items) and hyperactivity-impulsivity (9 items). If 3 or more items are skipped, the clinician should use extreme caution in interpreting the scale. Results from this rating scale alone should not be used to make a diagnosis. This subscale can range from 0 to 27 for scoring, with a higher score indicating greater severity. (NCT01238575)
Timeframe: Baseline
| Intervention | units on a scale (Mean) |
|---|---|
| Extended-release Guanfacine | 20.53 |
| Inactive Placebo | 20.41 |
The ADHD Rating Scale (ADHD-RS) is an 18-item scale directly derived from DSM-IV criteria for Attention Deficit Hyperactivity Disorder with established reliability, validity and sensitivity to change. The ADHD Rating Scale-IV is completed independently by the parent and scored by a clinician. The scale consists of 2 subscales: inattention (9 items) and hyperactivity-impulsivity (9 items). If 3 or more items are skipped, the clinician should use extreme caution in interpreting the scale. Results from this rating scale alone should not be used to make a diagnosis. The total score can range from 0 to 54, with a higher score indicating greater severity. (NCT01238575)
Timeframe: Baseline
| Intervention | units on a scale (Mean) |
|---|---|
| Extended-release Guanfacine | 39.53 |
| Inactive Placebo | 39.91 |
The ADHD Rating Scale (ADHD-RS) is an 18-item scale directly derived from DSM-IV criteria for Attention Deficit Hyperactivity Disorder with established reliability, validity and sensitivity to change. The ADHD Rating Scale-IV is completed independently by the parent and scored by a clinician. The scale consists of 2 subscales: inattention (9 items) and hyperactivity-impulsivity (9 items). If 3 or more items are skipped, the clinician should use extreme caution in interpreting the scale. Results from this rating scale alone should not be used to make a diagnosis. The total score can range from 0 to 54, with a higher score indicating greater severity. (NCT01238575)
Timeframe: Week 8
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Extended-release Guanfacine | 25.2 |
| Inactive Placebo | 38.0 |
4 reviews available for guanfacine and Child Development Disorders, Pervasive
| Article | Year |
|---|---|
[Autism and attention deficit hyperactivity disorder: pharmacological intervention].
Topics: Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivi | 2013 |
Alpha-2 adrenergic agonists in children with inattention, hyperactivity and impulsiveness.
Topics: Adrenergic alpha-Agonists; Attention Deficit Disorder with Hyperactivity; Child; Child Development D | 2009 |
Treatment of hyperactivity in children with pervasive developmental disorders.
Topics: Adrenergic alpha-Agonists; Amantadine; Attention Deficit Disorder with Hyperactivity; Central Nervou | 2007 |
Guanfacine and guanfacine extended release: treatment for ADHD and related disorders.
Topics: Adrenergic alpha-Agonists; Attention Deficit Disorder with Hyperactivity; Child; Child Development D | 2007 |
1 trial available for guanfacine and Child Development Disorders, Pervasive
| Article | Year |
|---|---|
Possible influence of variant of the P-glycoprotein gene (MDR1/ABCB1) on clinical response to guanfacine in children with pervasive developmental disorders and hyperactivity.
Topics: Adolescent; Adrenergic alpha-Agonists; ATP Binding Cassette Transporter, Subfamily B, Member 1; Atte | 2010 |
4 other studies available for guanfacine and Child Development Disorders, Pervasive
| Article | Year |
|---|---|
Guanfacine extended release in two patients with pervasive developmental disorders.
Topics: Adrenergic alpha-2 Receptor Agonists; Child; Child Development Disorders, Pervasive; Child, Preschoo | 2011 |
Guanfacine treatment of hyperactivity and inattention in pervasive developmental disorders: a retrospective analysis of 80 cases.
Topics: Adolescent; Adrenergic alpha-Agonists; Aging; Asperger Syndrome; Attention Deficit Disorder with Hyp | 2004 |
Methylphenidate an effective treatment for ADHD?
Topics: Adrenergic alpha-Agonists; Antipsychotic Agents; Attention Deficit Disorder with Hyperactivity; Auti | 2004 |
A prospective open trial of guanfacine in children with pervasive developmental disorders.
Topics: Adolescent; Adrenergic alpha-Agonists; Attention Deficit Disorder with Hyperactivity; Central Nervou | 2006 |
A prospective open trial of guanfacine in children with pervasive developmental disorders.
Topics: Adolescent; Adrenergic alpha-Agonists; Attention Deficit Disorder with Hyperactivity; Central Nervou | 2006 |
A prospective open trial of guanfacine in children with pervasive developmental disorders.
Topics: Adolescent; Adrenergic alpha-Agonists; Attention Deficit Disorder with Hyperactivity; Central Nervou | 2006 |
A prospective open trial of guanfacine in children with pervasive developmental disorders.
Topics: Adolescent; Adrenergic alpha-Agonists; Attention Deficit Disorder with Hyperactivity; Central Nervou | 2006 |
A prospective open trial of guanfacine in children with pervasive developmental disorders.
Topics: Adolescent; Adrenergic alpha-Agonists; Attention Deficit Disorder with Hyperactivity; Central Nervou | 2006 |
A prospective open trial of guanfacine in children with pervasive developmental disorders.
Topics: Adolescent; Adrenergic alpha-Agonists; Attention Deficit Disorder with Hyperactivity; Central Nervou | 2006 |
A prospective open trial of guanfacine in children with pervasive developmental disorders.
Topics: Adolescent; Adrenergic alpha-Agonists; Attention Deficit Disorder with Hyperactivity; Central Nervou | 2006 |
A prospective open trial of guanfacine in children with pervasive developmental disorders.
Topics: Adolescent; Adrenergic alpha-Agonists; Attention Deficit Disorder with Hyperactivity; Central Nervou | 2006 |
A prospective open trial of guanfacine in children with pervasive developmental disorders.
Topics: Adolescent; Adrenergic alpha-Agonists; Attention Deficit Disorder with Hyperactivity; Central Nervou | 2006 |